⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALT News
Altimmune, Inc. Common Stock
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
globenewswire.com
ALT
Altimmune Announces CEO Transition and Succession Plan
globenewswire.com
ALT
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
globenewswire.com
ALT
Alcohol Use Disorder Market to Grow Rapidly at a 13.6% CAGR by 2034 Owing to Rising Disease Prevalence, Significant Advancements in Genetically-targeted Therapies, along with Innovative Treatments such as GLP-1 Receptor Agonists | DelveInsight
prnewswire.com
ADIL
ATAI
ALKS
ALT
MDVN
Lifshitz Law PLLC Announces Investigations of Sable Offshore Corp. (NYSE: SOC), Lockheed Martin Corporation (NYSE: LMT), Altimmune, Inc. (NASDAQ: ALT), and Snap, Inc. (NYSE: SNAP)
accessnewswire.com
SOC
LMT
ALT
SNAP
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
globenewswire.com
ALT
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
globenewswire.com
ALT
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
globenewswire.com
ALT
Altimmune to Participate in Two Upcoming Investor Conferences
globenewswire.com
ALT
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
globenewswire.com
ALT